Arna Pharma Inc, an Australia-based global pharmaceutical company, and US-based Slate Run Pharmaceuticals, announced on Thursday that they have signed an MOU to establish a scaled-up United States based specialty pharmaceutical joint venture focused on branded products, 505(b)(2) medicines, and specialised generics.

The joint venture brings together Arna Pharma's development capabilities and portfolio expansion strategy with Slate Run Pharmaceuticals' established US commercial, regulatory, and supply chain infrastructure.

Ram Iyer, Arna Pharma Inc senior vice president, said, "This represents a significant milestone for Arna Pharma and a powerful step forward in our long-term strategy. By combining Arna's development expertise with Slate Run's proven US commercial and operational infrastructure, we have created a platform that is uniquely positioned to expand specialised generics in high-value therapeutic segments and accelerate market access, reimbursement, and physician engagement."

Michael Plessinger, Slate Run Pharmaceuticals CEO, said, "We are excited to unite our organisations and begin this next chapter together. This combination strengthens our ability to execute, expand our portfolio, and continue to serve as a trusted US partner for the industry."